Format

Send to

Choose Destination
BMC Med. 2017 Sep 20;15(1):170. doi: 10.1186/s12916-017-0936-z.

A 25-gene classifier predicts overall survival in resectable pancreatic cancer.

Author information

1
Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, Inserm UMR1068, CNRS UMR725, Aix-Marseille Université, Marseille, France.
2
Département de Chirurgie Générale et Viscérale, AP-HM, Marseille, France.
3
Faculté de Médecine, Aix-Marseille Université, Marseille, France.
4
Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France.
5
Département d'Anatomopathologie, Institut Paoli-Calmettes, Marseille, France.
6
Département d'Oncologie Chirurgicale, Institut Paoli-Calmettes, Marseille, France.
7
Département d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, Inserm UMR1068, CNRS UMR725, Aix-Marseille Université, Marseille, France. bertuccif@ipc.unicancer.fr.
8
Faculté de Médecine, Aix-Marseille Université, Marseille, France. bertuccif@ipc.unicancer.fr.
9
Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France. bertuccif@ipc.unicancer.fr.
10
Département d'Oncologie Moléculaire, Institut Paoli-Calmettes, 232 Bd. Ste-Marguerite, 13009, Marseille, France. bertuccif@ipc.unicancer.fr.

Abstract

BACKGROUND:

Pancreatic carcinoma is one of the most lethal human cancers. In patients with resectable tumors, surgery followed by adjuvant chemotherapy is the only curative treatment. However, the 5-year survival is 20%. Because of a strong metastatic propensity, neoadjuvant chemotherapy is being tested in randomized clinical trials. In this context, improving the selection of patients for immediate surgery or neoadjuvant chemotherapy is crucial, and high-throughput molecular analyses may help; the present study aims to address this.

METHODS:

Clinicopathological and gene expression data of 695 pancreatic carcinoma samples were collected from nine datasets and supervised analysis was applied to search for a gene expression signature predictive for overall survival (OS) in the 601 informative operated patients. The signature was identified in a learning set of patients and tested for its robustness in a large independent validation set.

RESULTS:

Supervised analysis identified 1400 genes differentially expressed between two selected patient groups in the learning set, namely 17 long-term survivors (LTS; ≥ 36 months after surgery) and 22 short-term survivors (STS; dead of disease between 2 and 6 months after surgery). From these, a 25-gene prognostic classifier was developed, which identified two classes ("STS-like" and "LTS-like") in the independent validation set (n = 562), with a 25% (95% CI 18-33) and 48% (95% CI 42-54) 2-year OS (P = 4.33 × 10-9), respectively. Importantly, the prognostic value of this classifier was independent from both clinicopathological prognostic features and molecular subtypes in multivariate analysis, and existed in each of the nine datasets separately. The generation of 100,000 random gene signatures by a resampling scheme showed the non-random nature of our prognostic classifier.

CONCLUSION:

This study, the largest prognostic study of gene expression profiles in pancreatic carcinoma, reports a 25-gene signature associated with post-operative OS independently of classical factors and molecular subtypes. This classifier may help select patients with resectable disease for either immediate surgery (the LTS-like class) or neoadjuvant chemotherapy (the STS-like class). Its assessment in the current prospective trials of adjuvant and neoadjuvant chemotherapy trials is warranted, as well as the functional analysis of the classifier genes, which may provide new therapeutic targets.

KEYWORDS:

Expression profiling; Pancreatic cancer; Prognosis; Survival

PMID:
28927421
PMCID:
PMC5606023
DOI:
10.1186/s12916-017-0936-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center